Incyte Price Target Lifted to $105 with Minjuvi Approval and Priority Review
INCY•INCY•INCY•INCY•Truist Financial raised its Incyte price target to $105, implying 1.73% upside. Incyte secured Japanese approval for Minjuvi® and received FDA Priority Review for Phase II zilurgisertib after positive results.
A Truist Financial analyst raised Incyte’s price target to $105, reflecting a 1.73% upside potential from previous levels.
Incyte secured regulatory approval in Japan for Minjuvi®, authorizing its use in adults with recurring blood cancer and expanding the company’s footprint in Asian oncology markets.
Positive Phase II data for zilurgisertib in rare bone disease prompted the FDA to accept the application and grant Priority Review, accelerating the anticipated approval timeline.
Following these developments, Incyte shares rose 5.54% on a trading volume of approximately 2.17 million shares, with a 12-month trading range of $66.74 to $112.29 and a market capitalization near $20.71 billion.
